• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

AI-Based Assessment Platform Ada Health Joins Forces with Pharma Giant Bayer

Share:

December 3, 2021

The partnership will help visitors to Bayer websites for Aspirin, Aleve, Midol, Canesten, and Iberogast to access Ada’s intelligent symptom assessment platform.

Using an AI-based health assessment platform, Berlin-based Ada Health assists users in identifying the correct care, based on their individual requirements, risk factors, and symptoms.

The free app provides guidance via an AI chatbot that asks users targeted questions that generate data-driven options and suggestions for the next steps in seeking healthcare.

WHY IT MATTERS

The partnership offers a digital solution so that people can be more proactive about preventative healthcare.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Digital health tools provide personalized insights and actionable medical guidance. People can look for guidance on health issues they may think too insignificant to take to a doctor.

Timely detection of diseases is one of the biggest challenges in guiding patients to appropriate care, with under-diagnosis and long patient journeys to diagnosis.

Shortening the time to diagnosis by providing medical guidance by using digital data can support the prediction and prevention of diseases.

THE LARGER TREND

The app essentially works like a WhatsApp chat with a trusted family doctor or medical professional but is available 24/7.

More than 11 million people worldwide have used Ada Health, completing over 25 million personal health assessments.

The symptom assessment app currently supports ten languages, but in the future, the aim is for a billion people to use the technology.

The app can be downloaded directly, or for people in the US, UK, or Germany, and it can be accessed via the Aspirin, Aleve, Midol, Canesten, and Iberogast websites.

In May, Ada Health clinched a $90 million (€79.7M) Series B round of funding from Bayer’s investment arm, Leaps by Bayer.

ON THE RECORD

“Ada’s technology is based on a custom-built reasoning engine and a highly comprehensive medical knowledge base, covering thousands of conditions. In fact, in a recent vignettes study testing the eight most popular online symptom assessment apps, Ada was proven to have the most comprehensive condition coverage, providing a condition suggestion 99% of the time, with high medical accuracy and safety of advice,” Vanessa Lemarié, Ada Health’s Chief Client Officer told MobiHealthNews.

“When it comes to women’s intimate health, for example, many feel embarrassed or uncomfortable reaching out to their GP or healthcare professional to discuss their symptoms. But with Ada, they can access trusted, high-quality health information from the comfort of their own home, via a simple, easy-to-use online tool,” Lemarié added.

“One of the exciting frontiers in healthcare is giving people the right tools, information, advice, and medicines to move from a reactive to a proactive approach to their own health,” said David Evendon-Challis, Chief Scientific Officer of Bayer’s Consumer Health division.

Source: Mobihealthnews

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • MicroGEM Acquires Jump Start, Expands Manufacturing To Accelerate Production Of Portable COVID-19 Saliva TestMicroGEM Acquires Jump Start, Expands Manufacturing To Accelerate Production Of Portable COVID-19 Saliva Test
  • CTAD 2022: Pivotal Anti-Amyloid Data and New Pathways (Updated)CTAD 2022: Pivotal Anti-Amyloid Data and New Pathways (Updated)
  • Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering.Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering.
  • Vistagen to Acquire Pherin PharmaceuticalsVistagen to Acquire Pherin Pharmaceuticals
  • CoorsTek Medical Becomes Lincotek MedicalCoorsTek Medical Becomes Lincotek Medical
  • Arena Pharmaceuticals and Beacon Discovery Expand Strategic Relationship Focusing on Multiple Immune and Inflammatory TargetsArena Pharmaceuticals and Beacon Discovery Expand Strategic Relationship Focusing on Multiple Immune and Inflammatory Targets
  • Zoetis Announces the Acquisition of Platinum Performance, a Leading Nutrition-Focused Animal Health Business for Equine and Petcare MarketsZoetis Announces the Acquisition of Platinum Performance, a Leading Nutrition-Focused Animal Health Business for Equine and Petcare Markets
  • The Path to Value-Based Care Through Patient EngagementThe Path to Value-Based Care Through Patient Engagement

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications